azd-5672
Small moleculeexperimental
Clinical trial activity
28 trials · 28 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
16
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00711074)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Arthritis, Rheumatoid · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biomarkers · Phase 1
- BRCA1 Protein · Phase 1/Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Drug Evaluation · Phase 1
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Glioma · Phase 2
- Hamartoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Kidney Failure, Chronic · Phase 1
- Kidney Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Mutation · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pharmacokinetics · Phase 1
- Pharmacological and Toxicological Phenomena · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Proteus Syndrome · Phase 1
- Proto-Oncogene Proteins c-akt · Phase 1
- PTEN Phosphohydrolase · Phase 1
- Skin Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Part of Astra Zeneca's Open Innovation program
Chemistry & pharmacology
Loading structure…
SMILES
CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1- Mol. weight
- 639.83 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2178577 ↗
- ChEMBLCHEMBL1951914 ↗
Also known as
- 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide
- azd5363
- azd5363
- azd5363
- azd-5363
- azd-5363
- azd-5363
- azd5672
- azd5672
- azd5672
- azd5672
- azd 5672
- azd-5672
- azd-5672
- azd-5672
- azd-5672
- n-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-n-ethyl-2-(4-methanesulfonylphenyl)acetamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03182634 | Phase 2 | Dec 15, 2016 | Royal Marsden Hospital NHS Trust, University of London |
| NCT02576444 | Phase 2 | Nov 1, 2015 | Harvard University, Vanderbilt University, Yale University |
| NCT02465060 | Phase 2 | Aug 12, 2015 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT02664935 | Phase 2 | Mar 1, 2015 | AstraZeneca, Cancer Research UK, Pfizer, University of Birmingham |
| NCT02449655 | Phase 2 | Feb 12, 2015 | Sungkyunkwan University |
| NCT02451956 | Phase 2 | Jan 7, 2015 | Sungkyunkwan University |
| NCT02525068 | Phase 2 | Dec 1, 2014 | Royal Marsden Hospital NHS Trust, University of London |
| NCT02208375 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | AstraZeneca, National Cancer Institute (NCI), University of Texas at Houston |
| NCT01992952 | Phase 1/Phase 2 (Phase 2) | May 1, 2014 | Cardiff University, University of Manchester, Velindre NHS Trust |
| NCT02423603 | Phase 2 | May 1, 2014 | AstraZeneca, Cancer Research UK, Royal Marsden Hospital NHS Trust, University of London |
| NCT02117167 | Phase 2 | Apr 23, 2014 | AstraZeneca, Fondation ARC, Groupe Hospitalier Paris Saint Joseph, Institut Gustave Roussy, UNICANCER |
| NCT02299999 | Phase 2 | Apr 7, 2014 | AstraZeneca, Fondation ARC, Institut Gustave Roussy, UNICANCER |
| NCT02338622 | Phase 1 | Mar 1, 2014 | AstraZeneca, Royal Marsden Hospital NHS Trust, University of London |
| NCT02077569 | Phase 2 | Jan 1, 2014 | AstraZeneca, Cancer Research UK, National Cancer Research Network, University of Nottingham |
| NCT02121639 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2014 | AstraZeneca, Cancer Research UK, Moorgreen Hospital, Southampton |
| NCT01895946 | Phase 1 | Dec 1, 2013 | AstraZeneca, University of London |
| NCT01692262 | Phase 1 | Nov 1, 2012 | AstraZeneca |
| NCT01625286 | Phase 1/Phase 2 (Phase 2) | Oct 3, 2012 | AstraZeneca |
| NCT01353781 | Phase 1 | Jun 1, 2011 | AstraZeneca |
| NCT01226316 | Phase 1 | Dec 1, 2010 | AstraZeneca, University of London |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (28)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 21 | 13 | 2 | 2008 |
| University of London | Academic/Hospital | 7 | 3 | 2 | 2009 |
| Cancer Research UK | Academic/Hospital | 4 | 0 | 1 | 2014 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 4 | 1 | 2 | 2014 |
| Parexel | For profit | 3 | 0 | 1 | 2008 |
| Fondation ARC | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Institut Gustave Roussy | Academic/Hospital | 2 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2014 |
| Sungkyunkwan University | Academic/Hospital | 2 | 2 | 1 | 2015 |
| UNICANCER | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Apex Bioscience | For profit | 1 | 0 | 1 | 2008 |
| Cardiff University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Groupe Hospitalier Paris Saint Joseph | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| ICON | For profit | 1 | 0 | 1 | 2009 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Cancer Research Network | Government | 1 | 0 | 1 | 2014 |
| Pfizer | For profit | 1 | 0 | 1 | 2015 |
28 organizations
Page 1 / 2